Action Sandoz - 0SAN

Sandoz Group AG (0SAN) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

( - )

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

567 384

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

Clôture Veille

0,00

Ouverture

Dernière Transaction

319

64.8897

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

CHF 734 251

Actions en circulation

432 692 617

Rendement du Dividende (LTM)

1,01

Ratio Cours sur Bénéfices

38,78

Bénéfice par action (BPA)

2,09

Chiffre d'affairess (LTM)

11,16B

Bénéfice net (LTM)

914M

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neu... Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. Show more

Secteur

Industrie

Site Web

www.sandoz.com

Siège social

Basel, Switzerland

Fondé

1886

Sandoz Group AG est coté dans le secteur de la London Stock Exchange avec le ticker 0SAN. Le dernier cours de clôture d'Sandoz était de CHF0,00. Au cours de la dernière année, les actions de Sandoz ont été négociées dans une fourchette de prix de CHF 0,00 à CHF 0,00.

Sandoz compte actuellement 432 692 617 actions en circulation. Sandoz a un ratio cours/bénéfice (ratio PE) de 38.78.

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations MEDIA RELEASE Sandoz signs 10-year...

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter Ad hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in...

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market...

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million...

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars MEDIA RELEASE Pyzchiva® first...

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed Ad-hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications...

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG All proposals of Board of...

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US Ad hoc announcement...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0SAN - Frequently Asked Questions (FAQ)

What is the current Sandoz Group AG share price?

The current share price of Sandoz Group AG is CHF 0,00

How many Sandoz Group AG shares are in issue?

Sandoz Group AG has 432 692 617 shares in issue

What is the 1 year trading range for Sandoz Group AG share price?

Sandoz Group AG has traded in the range of CHF 0,00 to CHF 0,00 during the past year

What is the PE ratio of Sandoz Group AG?

The price to earnings ratio of Sandoz Group AG is 38,78

What is the cash to sales ratio of Sandoz Group AG?

The cash to sales ratio of Sandoz Group AG is 3,14

What is the registered address of Sandoz Group AG?

The registered address for Sandoz Group AG is Centralbahnstrasse 4, Basel, Basel-Stadt, 4051

What is the Sandoz Group AG website address?

The website address for Sandoz Group AG is www.sandoz.com

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sandoz Group AG (0SAN)

Sandoz Group AG (0SAN) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Sandoz Group AG

0SAN Dernières nouvelles

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

0SAN - Frequently Asked Questions (FAQ)

0SAN Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sandoz Group AG (0SAN)

Sandoz Group AG (0SAN) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Sandoz Group AG

0SAN Dernières nouvelles

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

0SAN - Frequently Asked Questions (FAQ)

0SAN Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE